Next Article in Journal
How I Treat Relapsed and/or Refractory Multiple Myeloma
Previous Article in Journal
How I Manage Frontline Transplant-Ineligible Multiple Myeloma
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Hematology Reports
Volume 12
Issue s1
10.4081/hr.2020.8954
hematolrep-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles thumb_up
...
Endorse textsms
...
Comment
Hematology Reports is published by MDPI from Volume 14 Issue 1 (2022). Previous articles were published by another publisher in Open Access under a CC-BY (or CC-BY-NC-ND) licence, and they are hosted by MDPI on mdpi.com as a courtesy and upon agreement with PAGEPress.
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Conference Report

How I Manage Frontline Transplant-Eligible Multiple Myeloma in Italy

by
Vittorio Montefusco
1,*,
Giovanni Martinelli
2 and
Claudio Cerchione
2
1
Division of Onco-Hematology, ASST Santi Paolo e Carlo, 20153 Milan, Italy
2
Hematology Unit, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, 47014 Meldola, Italy
*
Author to whom correspondence should be addressed.
Hematol. Rep. 2020, 12(s1), 8954; https://doi.org/10.4081/hr.2020.8954
Submission received: 21 September 2020 / Revised: 21 September 2020 / Accepted: 21 September 2020 / Published: 21 September 2020

Abstract

The treatment of transplant-eligible multiple myeloma patients in Italy consists in an induction phase based on bortezomib plus thalidomide plus dexamethasone (VTd), followed by a single or tandem autologous stem cell transplantation (ASCT), followed by lenalidomide maintenance. This approach offers an overall response rate of 93% and a CR rate of 58% with acceptable toxicity. Lenalidomide maintenance adds a significant increase in disease control, with a progression free survival after ASCT of 53 months, and an overall survival of 86 months. Second primary malignancies represent the most concerning toxicity of lenalidomide maintenance with a 6.9% incidence. However, the benefit in terms of increased myeloma control largely outweigh this complication. The incorporation of daratumumab in this treatment schema will further improve these clinical results.
Keywords: Multiple myeloma, bortezomib, autologous stem cell transplantation, lenalidomide Multiple myeloma, bortezomib, autologous stem cell transplantation, lenalidomide

Share and Cite

MDPI and ACS Style

Montefusco, V.; Martinelli, G.; Cerchione, C. How I Manage Frontline Transplant-Eligible Multiple Myeloma in Italy. Hematol. Rep. 2020, 12, 8954. https://doi.org/10.4081/hr.2020.8954

AMA Style

Montefusco V, Martinelli G, Cerchione C. How I Manage Frontline Transplant-Eligible Multiple Myeloma in Italy. Hematology Reports. 2020; 12(s1):8954. https://doi.org/10.4081/hr.2020.8954

Chicago/Turabian Style

Montefusco, Vittorio, Giovanni Martinelli, and Claudio Cerchione. 2020. "How I Manage Frontline Transplant-Eligible Multiple Myeloma in Italy" Hematology Reports 12, no. s1: 8954. https://doi.org/10.4081/hr.2020.8954

APA Style

Montefusco, V., Martinelli, G., & Cerchione, C. (2020). How I Manage Frontline Transplant-Eligible Multiple Myeloma in Italy. Hematology Reports, 12(s1), 8954. https://doi.org/10.4081/hr.2020.8954

Article Metrics

Back to TopTop